Silizom 5gm Injection

Introduction

Silizom is a medication that contains the active ingredients L-Ornithine L-Aspartate. It is available under the brand name Silizom. This medication is primarily used to support liver function and improve hepatic encephalopathy.

Uses

Silizom is prescribed for the treatment of hepatic encephalopathy, a condition characterized by impaired brain function due to liver damage. It is commonly used in patients with liver cirrhosis, hepatitis, or liver failure to help reduce ammonia levels in the blood and improve neurological symptoms associated with hepatic encephalopathy.

Dosage and Administration

Silizom is administered by a healthcare professional through intravenous (IV) infusion. The dosage and duration of treatment will vary depending on the severity of hepatic encephalopathy and the patient’s individual response to the medication. Follow the instructions provided by your healthcare provider and not exceed the prescribed dose.

Mechanism of Action

The active ingredients in Silizom, L-Ornithine L-Aspartate, work by promoting the detoxification of ammonia in the liver. Ammonia is a waste product that is normally converted into urea and eliminated from the body. In patients with liver dysfunction, the liver is unable to efficiently convert ammonia, leading to its accumulation in the blood. L-Ornithine L-Aspartate helps enhance the urea cycle, facilitating the removal of excess ammonia and improving liver function.

Side Effects

Common side effects may include nausea, vomiting, diarrhea, abdominal pain, and headache. These side effects are usually mild and temporary. However, if they persist or worsen, consult your healthcare provider.

Serious side effects are rare but can occur. These may include allergic reactions, difficulty breathing, chest pain, or swelling of the face, lips, tongue, or throat. If you experience any of these symptoms, seek immediate medical attention.

Drug Interactions

Silizom may interact with certain medications, including diuretics (water pills) and potassium-sparing diuretics. Inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements, to avoid potential drug interactions. Your healthcare provider will carefully consider these interactions and adjust your treatment as necessary.

Precautions

Before using Silizom, inform your healthcare provider about any allergies you may have and your medical history, especially if you have kidney disease or any other liver-related conditions. This medication is not recommended for use in pregnant or breastfeeding women, unless specifically prescribed by a healthcare professional.

Storage

Silizom should be stored in a cool, dry place, away from direct sunlight and heat sources. It should be kept out of the reach of children and pets. Do not use the medication if the packaging is damaged or if the expiry date has passed. Proper disposal of unused or expired medications should be done in accordance with local regulations.

Patient Tips

• Follow the dosage instructions provided by your healthcare provider and do not exceed the prescribed dose.
• If you miss a dose, contact your healthcare provider for further guidance.
• Report any unusual or persistent side effects to your healthcare provider.
• Keep all follow-up appointments with your healthcare provider to monitor your progress and adjust your treatment if needed.
• Maintain a healthy lifestyle by following a balanced diet, exercising regularly, and avoiding alcohol and tobacco use, as these can further damage the liver.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Low blood sugar (hypoglycaemia) (NHS UK) [Accessed 3 Jun. 2024] (online) Available at:
• Numeta G13%E Preterm, emulsion for infusion (Health Professionals SmPC) Available at:
• Hepa-Merz (International database) (Drugs.com) [Accessed 21 Jun. 2024] (online) Available at:
• OTC gene (MedlinePlus) [Accessed 4 Jun. 2024] (online) Available at:
• Jain A, Sharma BC, Mahajan B, Srivastava S, Kumar A, Sachdeva S, Sonika U, Dalal A. L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: A double-blind randomized controlled trial. Hepatology. 2022 May;75(5):1194-1203. doi: 10.1002/hep.32255. Epub 2021 Dec 21. [Accessed 13 Jun. 2024] Available at: